Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 395-396

  Garland, P ^a   Dazzi, F ^a   Marin, D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB;

BLAST CELL CRISIS; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DONOR LYMPHOCYTE INFUSION; DRUG RESISTANCE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LETTER; LEUKEMIA REMISSION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

ADULT; BLAST CRISIS; FEMALE; GRAFT VS LEUKEMIA EFFECT; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE TRANSFUSION; PYRIMIDINES; THIAZOLES;

EID: 76749089556     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.136     Document Type: Letter

References (10)

1. Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia 2007; 21: 943-948.
2. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
3. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009-1015.
4. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332-1339.
5. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-1377.
6. Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14: 2484-2491.
7. Blake SJ, Bruce LA, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111: 4415-4416.
8. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Gotz M et al. Dasatinib inhibits the proliferation and function of CD4CD25 regulatory T cells. Br J Haematol 2009; 144: 195-205.
9. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207-3213.
10. Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F. Increased frequencies of CD4 CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2007; 21: 472-479.